128 related articles for article (PubMed ID: 33590608)
1. Effectiveness of direct-acting antivirals for chronic hepatitis C treatment in migrant and non-migrant populations in France.
Djaogol T; Fontaine H; Baudoin M; Protopopescu C; Marcellin F; Dorival C; Simony M; Petrov-Sanchez V; Bourlière M; Delarocque-Astagneau E; Pol S; Carrat F; Carrieri P;
Liver Int; 2021 Oct; 41(10):2328-2340. PubMed ID: 33590608
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of test-and-treat model with direct-acting antiviral for hepatitis C virus infection in migrants: a prospective interventional study in Italy.
Coppola N; Alessio L; De Pascalis S; Macera M; Di Caprio G; Messina V; Onorato L; Minichini C; Stanzione M; Stornaiuolo G; Starace M; Monari C; Calò F; Sagnelli C; Pisaturo M
Infect Dis Poverty; 2024 May; 13(1):39. PubMed ID: 38802954
[TBL] [Abstract][Full Text] [Related]
3. Impaired health-related quality of life in the HCV cure era: who is concerned? (ANRS CO22 HEPATHER French cohort).
Carrieri P; Bourlière M; Di Beo V; Lusivika-Nzinga C; Ramier C; Antwerpes S; Protopopescu C; Lacombe JM; Pol S; Fontaine H; Mourad A; Carrat F; Duracinsky M; Marcellin F;
Qual Life Res; 2023 Dec; 32(12):3427-3438. PubMed ID: 37587323
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis C virus cure from direct-acting antivirals and mortality: Are people with and without a history of injection drug use in the same boat? (ANRS CO22 Hepather cohort).
Barré T; Bourlière M; Parlati L; Ramier C; Marcellin F; Protopopescu C; Di Beo V; Cagnot C; Dorival C; Nicol J; Zoulim F; Carrat F; Carrieri P;
Drug Alcohol Rev; 2024 Mar; 43(3):718-731. PubMed ID: 38133601
[TBL] [Abstract][Full Text] [Related]
5. Lower HCV treatment uptake in women who have received opioid agonist therapy before and during the DAA era: The ANRS FANTASIO project.
Rojas Rojas T; Di Beo V; Delorme J; Barre T; Mathurin P; Protopopescu C; Bailly F; Coste M; Authier N; Carrieri MP; Rolland B; Marcellin F
Int J Drug Policy; 2019 Oct; 72():61-68. PubMed ID: 31129024
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study.
Carrat F; Fontaine H; Dorival C; Simony M; Diallo A; Hezode C; De Ledinghen V; Larrey D; Haour G; Bronowicki JP; Zoulim F; Asselah T; Marcellin P; Thabut D; Leroy V; Tran A; Habersetzer F; Samuel D; Guyader D; Chazouilleres O; Mathurin P; Metivier S; Alric L; Riachi G; Gournay J; Abergel A; Cales P; Ganne N; Loustaud-Ratti V; D'Alteroche L; Causse X; Geist C; Minello A; Rosa I; Gelu-Simeon M; Portal I; Raffi F; Bourliere M; Pol S;
Lancet; 2019 Apr; 393(10179):1453-1464. PubMed ID: 30765123
[TBL] [Abstract][Full Text] [Related]
7. Cascade of care for migrants tested Hepatitis C antibodies positive in France through a systematic screening programme: The PRECAVIR study.
Rosa-Hezode I; Chousterman M; Costes L; Labourdette C; Elghozi B; Krastinova E; Roudot-Thoraval F
J Viral Hepat; 2019 Dec; 26(12):1496-1499. PubMed ID: 31433886
[TBL] [Abstract][Full Text] [Related]
8. Real-world economic burden of hepatitis C and impact of direct-acting antivirals in France: A nationwide claims data analysis.
Lam L; Carrieri P; Hejblum G; Bellet J; Bourlière M; Carrat F
Liver Int; 2024 May; 44(5):1233-1242. PubMed ID: 38375961
[TBL] [Abstract][Full Text] [Related]
9. Characteristics and care of chronic hepatitis C treated with direct-acting antivirals in migrants.
Doffoel M; Ernwein F; Chaffraix F; Haumesser L; Tripon S; Bader R; Lang JP; Lang A; Paya D; Royant M; Velay-Rusch A; Tebacher M; Meyer N; Habersetzer F; Baumert T
Eur J Gastroenterol Hepatol; 2022 Jun; 34(6):664-670. PubMed ID: 34974466
[TBL] [Abstract][Full Text] [Related]
10. Minimal clinically important differences in health-related quality of life after treatment with direct-acting antivirals for chronic hepatitis C: ANRS CO22 HEPATHER cohort (PROQOL-HCV).
Abbas M; Patrizia C; Fabienne M; Marc B; Lucia P; Fabrice C; Martin D; Camelia P
Qual Life Res; 2024 Jun; 33(6):1527-1540. PubMed ID: 38580786
[TBL] [Abstract][Full Text] [Related]
11. Untreated alcohol use disorder in people who inject drugs (PWID) in France: a major barrier to HCV treatment uptake (the ANRS-FANTASIO study).
Barré T; Marcellin F; Di Beo V; Delorme J; Rojas Rojas T; Mathurin P; Protopopescu C; Bailly F; Coste M; Authier N; Carrieri MP; Rolland B
Addiction; 2020 Mar; 115(3):573-582. PubMed ID: 31595554
[TBL] [Abstract][Full Text] [Related]
12. Adherence to opioid agonist therapy predicts uptake of direct-acting antivirals in people who use drugs: results from the French national healthcare database (the ANRS FANTASIO study).
Rolland B; Lions C; Di Beo V; Carrieri P; Authier N; Barré T; Delorme J; Mathurin P; Bailly F; Protopopescu C; Marcellin F
Harm Reduct J; 2022 Oct; 19(1):119. PubMed ID: 36303159
[TBL] [Abstract][Full Text] [Related]
13. Early View of the Effectiveness of New Direct-Acting Antiviral (DAA) Regimens in Patients with Hepatitis C Virus (HCV).
Walker DR; Pedrosa MC; Manthena SR; Patel N; Marx SE
Adv Ther; 2015 Nov; 32(11):1117-27. PubMed ID: 26538232
[TBL] [Abstract][Full Text] [Related]
14. Recently acquired hepatitis C virus infection among people living with human immunodeficiency virus at a university hospital in Taiwan.
Huang MH; Sun HY; Ho SY; Chang SY; Hsieh SM; Sheng WH; Chuang YC; Huang YS; Su LH; Liu WC; Su YC; Hung CC
World J Gastroenterol; 2021 Oct; 27(37):6277-6289. PubMed ID: 34712032
[TBL] [Abstract][Full Text] [Related]
15. Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort.
Quaranta MG; Ferrigno L; Tata X; D'Angelo F; Massari M; Coppola C; Biliotti E; Giorgini A; Laccabue D; Ciancio A; Blanc PL; Margotti M; Ieluzzi D; Brunetto MR; Barbaro F; Russo FP; Beretta I; Morsica G; Verucchi G; Saracino A; Galli M; Kondili LA;
Dig Liver Dis; 2021 Dec; 53(12):1603-1609. PubMed ID: 33893040
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant ribavirin and longer direct-acting antiviral treatment duration improve sustained virological response among hepatitis C patients at risk of treatment failure.
Lu M; Wu KH; Li J; Moorman AC; Spradling PR; Teshale EH; Boscarino JA; Daida YG; Schmidt MA; Rupp LB; Zhang T; Trudeau S; Gordon SC
J Viral Hepat; 2019 Oct; 26(10):1210-1217. PubMed ID: 31197910
[TBL] [Abstract][Full Text] [Related]
17. Global cascade of care for chronic hepatitis C virus infection: A systematic review and meta-analysis.
Yousafzai MT; Bajis S; Alavi M; Grebely J; Dore GJ; Hajarizadeh B
J Viral Hepat; 2021 Oct; 28(10):1340-1354. PubMed ID: 34310812
[TBL] [Abstract][Full Text] [Related]
18. Human Immunodeficiency Virus (HIV) Infection Is Associated With Lower Risk of Hepatocellular Carcinoma After Sustained Virological Response to Direct-acting Antivirals in Hepatitis C Infected Patients With Advanced Fibrosis.
Corma-Gómez A; Macías J; Lacalle-Remigio JR; Téllez F; Morano L; Rivero A; Serrano M; Ríos MJ; Vera-Méndez FJ; Alados JC; Real LM; Palacios R; Santos IL; Imatz A; Pineda JA;
Clin Infect Dis; 2021 Oct; 73(7):e2109-e2116. PubMed ID: 32766891
[TBL] [Abstract][Full Text] [Related]
19. Direct-acting antiviral treatment against hepatitis C virus infection in HIV-Infected patients - "En route for eradication"?
Pradat P; Pugliese P; Poizot-Martin I; Valantin MA; Cuzin L; Reynes J; Billaud E; Huleux T; Bani-Sadr F; Rey D; Frésard A; Jacomet C; Duvivier C; Cheret A; Hustache-Mathieu L; Hoen B; Cabié A; Cotte L;
J Infect; 2017 Sep; 75(3):234-241. PubMed ID: 28579302
[TBL] [Abstract][Full Text] [Related]
20. Sofosbuvir-Daclatasvir is suboptimal in patients with genotype 2 chronic hepatitis C infection: real-life experience from the HEPATHER ANRS CO22 cohort.
de Lédinghen V; Lusivika-Nzinga C; Bronowicki JP; Zoulim F; Larrey D; Metivier S; Tran A; Marcellin P; Samuel D; Chazouillères O; Chevaliez S; Dorival C; Fontaine H; Pawlotsky JM; Carrat F; Pol S;
J Viral Hepat; 2020 Oct; 27(10):964-973. PubMed ID: 32436335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]